GLN-GABAPENTIN

glenmark pharmaceuticals canada inc.🇨🇦 Health Canada

Approval Id: 855fc33ac9e0adfe
Drug Approval Canada Name: GLN-GABAPENTIN
Product Name: GLN-GABAPENTIN
Status: Marketed
Status Date: 2019-09-27
Original Market Date: 2016-04-04
Din: 02410990
Drug Class: Human
Dosage Form: Tablet
Route Of Administration: Oral
Schedule: Prescription
Ahfs: 28:12.92
Atc Original: N02BF01 GABAPENTIN
Atc Name: n 02 bf 01
Aig Number: 0125929004
Company Name: glenmark pharmaceuticals canada inc.
Company Address: 1600 Steeles Ave. W., Suite 407, Concord, Ontario, Canada, L4K 4M2

GABAPENTIN

600 MG

Authorized

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

855fc33ac9e0adfe

Type

Standard